Prometheus Stock Analysis

RXDX -  USA Stock  

USD 35.29  5.16  17.13%

The current price rise of Prometheus Biosciences created some momentum for investors as it was traded today as low as 29.57 and as high as 35.4 per share. The company directors and management may have good odds in positioning the company resources to exploit market volatility in February. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.71. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Prometheus Biosciences partners.
Additionally, take a look at Your Equity Center.

Prometheus Stock Analysis 

 
Refresh
The Prometheus Biosciences stock analysis report makes it easy to digest most publicly released information about Prometheus Biosciences and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Prometheus Stock analysis module also helps to analyze the Prometheus Biosciences price relationship with some important fundamental indicators such as market cap and management efficiency.

Prometheus Stock Analysis Notes

About 35.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 3.13. Prometheus Biosciences had not issued any dividends in recent years. The entity had 1:100 split on the 1st of November 2013. Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of precision therapeutics and companion diagnostics products for the treatment and diagnosis of inflammatory bowel diseases . The company was founded in 2016 and is based in San Diego, California. Prometheus Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 24 people. To find out more about Prometheus Biosciences contact Jonathan Lim at 858 255-5959 or learn more at https://www.prometheusbiosciences.com.

Prometheus Biosciences Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Prometheus Biosciences' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Prometheus Biosciences or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Prometheus Biosciences is way too risky over 90 days horizon
Prometheus Biosciences appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 2.56 M. Net Loss for the year was (69.48 M) with loss before overhead, payroll, taxes, and interest of (17.92 M).
Prometheus Biosciences currently holds about 279.12 M in cash with (46.65 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.17.
Prometheus Biosciences has a frail financial position based on the latest SEC disclosures
Roughly 68.0% of the company shares are owned by institutional investors

Prometheus Biosciences Upcoming and Recent Events

Earnings reports are used by Prometheus Biosciences to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Prometheus Biosciences previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report11th of February 2022
Next Earnings Report12th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End11th of February 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Prometheus Largest EPS Surprises

Earnings surprises can significantly impact Prometheus Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-08-11
2021-06-30-0.39-0.49-0.125 
2021-11-12
2021-09-30-0.588-0.7-0.11219 
View All Earnings Estimates

Prometheus Biosciences Thematic Classifications

In addition to having Prometheus Biosciences stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Cancer Fighters IdeaCancer Fighters
Public companies from health care and pharmaceutical sectors that are focused on fighting cancer
Cancer Fighters IdeaCancer Fighters
Public companies from health care and pharmaceutical sectors that are focused on fighting cancer

Prometheus Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 1.31 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Prometheus Biosciences's market, we take the total number of its shares issued and multiply it by Prometheus Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Prometheus Profitablity

Prometheus Biosciences' profitability indicators refer to fundamental financial ratios that showcase Prometheus Biosciences' ability to generate income relative to its revenue or operating costs. If, let's say, Prometheus Biosciences is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Prometheus Biosciences' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Prometheus Biosciences' profitability requires more research than a typical breakdown of Prometheus Biosciences' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Investment(93.47) (100.85) 
Return on Average Assets(54.70) (59.02) 
Return on Average Equity(80.84) (87.23) 
Return on Invested Capital(0.64) (0.69) 
Return on Sales(239.94) (258.88) 

Management Efficiency

The entity has return on total asset (ROA) of (32.93) % which means that it has lost $32.93 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (176.65) %, meaning that it created substantial loss on money invested by shareholders. Prometheus Biosciences management efficiency ratios could be used to measure how well prometheus biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return on Investment is likely to drop to -100.85 in 2022. Return on Average Assets is likely to drop to -59.02 in 2022. Prometheus Biosciences Total Assets are fairly stable at the moment as compared to the past year. Prometheus Biosciences reported Total Assets of 130.42 Million in 2021. Current Assets is likely to rise to about 108.6 M in 2022, whereas Total Assets Per Share are likely to drop 2.93 in 2022.
Last ReportedProjected for 2022
Book Value per Share 4.99  6.33 
Enterprise Value over EBIT(4.60) (4.96) 
Enterprise Value over EBITDA(4.84) (5.22) 
Price to Book Value 2.63  2.51 
Tangible Assets Book Value per Share 7.18  8.63 
Enterprise Value332.8 M281 M
Tangible Asset Value176 M189.9 M

Technical Drivers

As of the 18th of January 2022, Prometheus Biosciences holds the Risk Adjusted Performance of 0.1058, coefficient of variation of 833.5, and Semi Deviation of 5.32. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Prometheus Biosciences, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to break down nineteen technical drivers for Prometheus Biosciences, which can be compared to its competitors. Please check Prometheus Biosciences variance and potential upside to decide if Prometheus Biosciences is priced some-what accurately, providing market reflects its current price of 35.29 per share. Given that Prometheus Biosciences has jensen alpha of 0.605, we recommend you to check out Prometheus Biosciences's recent market performance to make sure the company can sustain itself at a future point.

Prometheus Biosciences Price Movement Analysis

The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Prometheus Biosciences middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Prometheus Biosciences. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target. View also all equity analysis or get more info about bollinger bands overlap studies indicator.

Prometheus Biosciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Prometheus Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Prometheus Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Prometheus Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mckenna Mark C over a month ago via Macroaxis 
Exercise or conversion by Mckenna Mark C of 15400 shares of Prometheus Biosciences subject to Rule 16b-3
Luo Allison over two months ago via Macroaxis 
Acquisition by Luo Allison of 113677 shares of Prometheus Biosciences subject to Rule 16b-3
Luo Allison over three months ago via Macroaxis 
Acquisition by Luo Allison of 4500 shares of Prometheus Biosciences subject to Rule 16b-3
Cedars Sinai Intellectual Property Co over six months ago via Macroaxis 
Prometheus Biosciences exotic insider transaction detected
Hassan Fred over six months ago via Macroaxis 
Acquisition by Hassan Fred of 40000 shares of Prometheus Biosciences subject to Rule 16b-3
Hendrix Martin over six months ago via Macroaxis 
Acquisition by Hendrix Martin of 40000 shares of Prometheus Biosciences subject to Rule 16b-3
Cormorant Asset Management Lp over six months ago via Macroaxis 
Conversion by Cormorant Asset Management Lp of 1084696 shares of Prometheus Biosciences
Point72 Biotech Private Investments Llc over six months ago via Macroaxis 
Conversion by Point72 Biotech Private Investments Llc of 10846968 shares of Prometheus Biosciences
Stenhouse Mark over six months ago via Macroaxis 
Purchase by Stenhouse Mark of 14000 shares of Prometheus Biosciences
Jonathan Lim over a year ago via Macroaxis 
Disposition of 120000 shares by Jonathan Lim of Ignyta subject to Rule 16b-3
Jonathan Lim over a year ago via Macroaxis 
Ignyta exotic insider transaction detected
Zachary Hornby over a year ago via Macroaxis 
Ignyta exotic insider transaction detected

Prometheus Biosciences Technical and Predictive Indicators

Prometheus Biosciences Forecast Models

Prometheus Biosciences time-series forecasting models is one of many Prometheus Biosciences' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Prometheus Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Prometheus Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Prometheus Biosciences stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Prometheus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Prometheus Biosciences. By using and applying Prometheus Stock analysis, traders can create a robust methodology for identifying Prometheus entry and exit points for their positions.
Last ReportedProjected for 2022
Gross Margin 0.90  0.89 
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of precision therapeutics and companion diagnostics products for the treatment and diagnosis of inflammatory bowel diseases . The company was founded in 2016 and is based in San Diego, California. Prometheus Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 24 people.

Current Prometheus Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Prometheus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Prometheus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
45.0Buy6Odds
Prometheus Biosciences current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Prometheus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Prometheus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Prometheus Biosciences, talking to its executives and customers, or listening to Prometheus conference calls.
Prometheus Analyst Advice Details

Prometheus Stock Analysis Indicators

Prometheus Biosciences stock analysis indicators help investors evaluate how Prometheus Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Prometheus Biosciences shares will generate the highest return on investment. By understating and applying Prometheus Biosciences stock analysis, traders can identify Prometheus Biosciences position entry and exit signals to maximize returns.
Quick Ratio18.54
Fifty Two Week Low16.11
Revenue Growth180.20%
Shares Short Prior Month897.89k
Average Daily Volume Last 10 Day130.66k
Average Daily Volume In Three Month267.94k
Shares Percent Shares Out2.80%
Short Percent Of Float3.62%
Forward Price Earnings-11.95
Float Shares18.01M
Fifty Two Week High40.49
Enterprise Value To Ebitda-20.19
Fifty Day Average34.27
Two Hundred Day Average25.95
Enterprise Value To Revenue472.64
Additionally, take a look at Your Equity Center. Note that the Prometheus Biosciences information on this page should be used as a complementary analysis to other Prometheus Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Complementary Tools for Prometheus Stock analysis

When running Prometheus Biosciences price analysis, check to measure Prometheus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prometheus Biosciences is operating at the current time. Most of Prometheus Biosciences' value examination focuses on studying past and present price action to predict the probability of Prometheus Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Prometheus Biosciences' price. Additionally, you may evaluate how the addition of Prometheus Biosciences to your portfolios can decrease your overall portfolio volatility.
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Is Prometheus Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prometheus Biosciences. If investors know Prometheus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prometheus Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Prometheus Biosciences is measured differently than its book value, which is the value of Prometheus that is recorded on the company's balance sheet. Investors also form their own opinion of Prometheus Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Prometheus Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prometheus Biosciences' market value can be influenced by many factors that don't directly affect Prometheus Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prometheus Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Prometheus Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prometheus Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.